San Francisco Based Lab Raises $2 Million with Orphan Drug Developer Retrophin and the Wilsey Family for Rare Disease Drug Research

The Perlstein Lab Raises $2 Million for the Production of Treatments for Rare Diseases

In Clinical Development, Partnering & Investment by Cecile

San Francisco Based Lab Raises $2 Million with Orphan Drug Developer Retrophin and the Wilsey Family for Rare Disease Drug Research

Perlstein Lab, in cooperation with orphan drug pharmaceutical company ‘Retrophin’ and the privileged Wilsey family, has raised $2 Million for research into treatments and drugs for rare diseases.

Perlstein labs specialise in small-drugs and other candidates that are patient specific and thus tailor made to the patients unique genetic mutation(s) and/or condition.

The lab is able to research patient specific disease causing mutations by using animal models to recreate these mutations.

These preclinical studies allow a large volume of data to be produced which can help generate research leads and starting points for drug candidates.

Read more about it here: Perlstein Lab raises $2 million towards production of treatments for rare conditions